Physician profile
Ramiro Guillen
NPI 1104993500
$30,810.09
in general payments reported to CMS, 2019-2025
19 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $384 · 2021: $3,530 · 2022: $838 · 2023: $439 · 2024: $271 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15,058.51 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $9,792.75 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $2,864.47 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $685.31 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $519.42 | 2019-2023 | Rexulti, Abilify Maintena |
| Corium, LLC | $437.84 | 2022-2025 | Azstarys |
| Alkermes, INC. | $320.76 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $315.83 | 2019-2021 | |
| Abbvie INC. | $164.02 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.50 | 2022-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $139.24 | 2022-2023 | Ingrezza |
| Shire North American Group INC | $112.56 | 2019 | |
| Brainsway USA INC | $89.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $47.91 | 2022-2023 | Austedo |
| Vanda Pharmaceuticals INC. | $45.11 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $27.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.79 | 2019 | |
| Lilly USA, LLC | $16.78 | 2024 | Zepbound |
| Neos Therapeutics, LP | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramiro Guillen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.